Subject(s)
4-Aminobenzoic Acid/pharmacology , Cypriniformes/embryology , Embryonic Development/drug effects , Oxidative Stress , Proteasome Endopeptidase Complex/drug effects , Vitamin B Complex/pharmacology , Animals , Blotting, Western , Cypriniformes/growth & development , Embryonic Development/physiology , Proteasome Endopeptidase Complex/metabolismABSTRACT
Cystatin C is a low-molecular endogenous inhibitor of cysteic proteinases. Sets for immune-enzyme assay of cystatin C in human blood serum (KRKK, Slovenia) were made used of in the case study. The concentration of cystatin C (CCC) in blood serum was found to be higher in cases of certain hemoblastoses (Non-Hodgkin's disease, lymphogranulomatosis and multiple myeloma), with the highest concentration of the inhibitor being observed in patients with resistance to the conducted polychemotherapy and a poor prognostication. The treatment of Non-Hodgkin's disease and of lymphogranulomatosis brought about a normalized CCC in blood serum. It was suggested that CCC in blood serum reflects a nature of tumor growth and, obviously, it can be a criterion in assessing the therapy efficiency. The concentration of alpha 1-proteinases inhibitor remained unchanged before and after treatment.
Subject(s)
Biomarkers, Tumor/blood , Cystatins/blood , Hematologic Neoplasms/blood , Acute Disease , Adrenal Gland Diseases/blood , Adrenal Gland Diseases/drug therapy , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cystatin C , Drug Resistance, Neoplasm , Hematologic Neoplasms/drug therapy , Hodgkin Disease/blood , Hodgkin Disease/drug therapy , Humans , Immunoenzyme Techniques , Leukemia/blood , Leukemia/drug therapy , Lymphoma, Non-Hodgkin/blood , Lymphoma, Non-Hodgkin/drug therapy , Multiple Myeloma/blood , Multiple Myeloma/drug therapy , Treatment OutcomeABSTRACT
We measured plasma cystatin C concentration and activity of cathepsins B and L in tumor tissue as possible markers for the efficiency of antitumor therapy and prognostic criteria for Lewis lung adenocarcinoma in mice. Plasma cystatin C concentration markedly decreased in mice with tumors. During successive therapy the increase in plasma cystatin C concentration correlated with the degree of inhibition of tumor growth. Activities of cathepsins B and L in the liver increased in animals with tumors. In mice receiving successive antitumor therapy activities of cathepsins B and L increased in tumor tissue, but decreased in the liver (compared to untreated animals).
Subject(s)
Carcinoma, Lewis Lung/blood , Cathepsin B/blood , Cathepsins/blood , Cystatins/blood , Animals , Antineoplastic Agents, Alkylating/therapeutic use , Biomarkers, Tumor/blood , Carcinoma, Lewis Lung/drug therapy , Cathepsin L , Cyclophosphamide/therapeutic use , Cystatin C , Cysteine Endopeptidases , Male , Mice , PrognosisABSTRACT
We measured activities of cysteine (cathepsins B and L) and aspartyl proteinases (cathepsin D) in tumor tissue of mice with sensitive and resistant lymphosarcomas. In cyclophosphamide-resistant lymphosarcoma tissue activities of cathepsins B, L, and D were lower than in cyclophosphamide-sensitive lymphosarcoma. After treatment with cyclophosphamide in high doses enzyme activities in mice with cyclophosphamide-resistant lymphosarcoma increased more significantly than in animals with cyclophosphamide-sensitive lymphosarcoma. Sulfoethylated beta-1,3-D-glycan potentiated the effect of cyclophosphamide in mice with both forms of lymphosarcoma. This drug in the lowest dose (10 mg/kg) was most effective.